TAXATION
Mutual Fund Distributions: How Capital Gain Distributions Are Taxed
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
Hartford Healthcare R6
- HGHVX
- Price as of: Oct 26, 2020
-
$50.51
N/A N/A
- Primary Theme
- Health Care Sector Equity
- Fund Company
- Hartford
- Share Class
HGHVX - Snapshot
Vitals
- YTD Return 13.6%
- 3 Yr Annualized Return 12.6%
- 5 Yr Annualized Return 12.5%
- Net Assets $1.52 B
- Holdings in Top 10 40.7%
52 WEEK LOW AND HIGH
$50.51
$32.74
$51.61
Expenses
OPERATING RELATED FEES
- Expense Ratio 0.91%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 35.00%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $0
- IRA N/A
Fund Classification
-
Primary Theme
Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
HGHVX - Profile
Distributions
- YTD Total Return 13.6%
- 3 Yr Annualized Total Return 12.6%
- 5 Yr Annualized Total Return 12.5%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio 0.06%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameThe Hartford Healthcare Fund
-
Fund Family NameHartford Mutual Funds
-
Inception DateFeb 28, 2019
-
Shares OutstandingN/A
-
Share ClassRetirement
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerRobert Deresiewicz
Fund Description
Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP ("Wellington Management"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.
HGHVX - Performance
Return Ranking - Trailing
| Period | HGHVX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 13.6% | -8.3% | 112.0% | 36.42% |
| 1 Yr | 33.1% | 8.3% | 128.7% | 35.40% |
| 3 Yr | 12.6%* | 0.1% | 38.7% | 31.47% |
| 5 Yr | 12.5%* | 0.4% | 30.0% | 25.18% |
| 10 Yr | 16.9%* | 8.9% | 20.1% | 32.52% |
* Annualized
Return Ranking - Calendar
| Period | HGHVX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | N/A | 3.8% | 63.8% | N/A |
| 2018 | N/A | -49.7% | 21.5% | N/A |
| 2017 | N/A | -59.8% | 54.4% | N/A |
| 2016 | N/A | -36.6% | 11.6% | N/A |
| 2015 | N/A | -62.4% | 27.9% | N/A |
Total Return Ranking - Trailing
| Period | HGHVX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 13.6% | -8.3% | 106.2% | 35.19% |
| 1 Yr | 33.1% | 2.7% | 128.7% | 31.68% |
| 3 Yr | 12.6%* | 0.1% | 38.7% | 30.07% |
| 5 Yr | 12.5%* | 0.4% | 30.0% | 22.30% |
| 10 Yr | 16.9%* | 8.9% | 20.1% | 31.71% |
* Annualized
Total Return Ranking - Calendar
| Period | HGHVX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | N/A | 3.8% | 63.8% | N/A |
| 2018 | N/A | -25.3% | 22.2% | N/A |
| 2017 | N/A | -10.8% | 54.4% | N/A |
| 2016 | N/A | -36.6% | 11.6% | N/A |
| 2015 | N/A | -16.6% | 27.9% | N/A |
NAV & Total Return History
HGHVX - Holdings
Concentration Analysis
| HGHVX | Category Low | Category High | HGHVX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.52 B | 2.6 M | 48.7 B | 34.10% |
| Number of Holdings | 119 | 26 | 431 | 23.12% |
| Net Assets in Top 10 | 617 M | 670 K | 18.8 B | 41.04% |
| Weighting of Top 10 | 40.68% | 13.2% | 76.3% | 53.76% |
Top 10 Holdings
- UnitedHealth Group Inc 7.77%
- Pfizer Inc 5.86%
- Thermo Fisher Scientific Inc 4.37%
- Danaher Corp 3.65%
- Bristol-Myers Squibb Company 3.65%
- Abbott Laboratories 3.57%
- Eli Lilly and Co 3.55%
- Boston Scientific Corp 2.99%
- AstraZeneca PLC ADR 2.69%
- Edwards Lifesciences Corp 2.58%
Asset Allocation
| Weighting | Return Low | Return High | HGHVX % Rank | |
|---|---|---|---|---|
| Stocks | 97.17% | 61.47% | 100.59% | 68.21% |
| Cash | 2.84% | -0.68% | 32.46% | 23.70% |
| Preferred Stocks | 0.00% | 0.00% | 6.63% | 65.90% |
| Other | 0.00% | -3.06% | 6.07% | 64.74% |
| Convertible Bonds | 0.00% | 0.00% | 0.03% | 57.80% |
| Bonds | 0.00% | 0.00% | 16.11% | 59.54% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | HGHVX % Rank | |
|---|---|---|---|---|
| Healthcare | 99.93% | 61.81% | 100.00% | 39.88% |
| Financial Services | 0.07% | 0.00% | 2.72% | 29.48% |
| Utilities | 0.00% | 0.00% | 0.00% | 56.65% |
| Technology | 0.00% | 0.00% | 20.28% | 64.16% |
| Real Estate | 0.00% | 0.00% | 6.03% | 61.27% |
| Industrials | 0.00% | 0.00% | 6.39% | 60.69% |
| Energy | 0.00% | 0.00% | 0.00% | 56.65% |
| Communication Services | 0.00% | 0.00% | 3.21% | 58.96% |
| Consumer Defense | 0.00% | 0.00% | 34.31% | 60.12% |
| Consumer Cyclical | 0.00% | 0.00% | 1.21% | 62.43% |
| Basic Materials | 0.00% | 0.00% | 2.61% | 72.83% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | HGHVX % Rank | |
|---|---|---|---|---|
| US | 79.25% | 47.91% | 100.00% | 62.43% |
| Non US | 17.92% | 0.00% | 43.87% | 48.55% |
HGHVX - Expenses
Operational Fees
| HGHVX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.91% | 0.08% | 25.14% | 58.43% |
| Management Fee | 0.86% | 0.00% | 1.25% | 84.97% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.40% | N/A |
Sales Fees
| HGHVX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| HGHVX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| HGHVX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 35.00% | 0.70% | 252.00% | 48.78% |
HGHVX - Distributions
Dividend Yield Analysis
| HGHVX | Category Low | Category High | HGHVX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.15% | 66.47% |
Dividend Distribution Analysis
| HGHVX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Net Income Ratio Analysis
| HGHVX | Category Low | Category High | HGHVX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.06% | -2.53% | 2.53% | 46.11% |
Capital Gain Distribution Analysis
| HGHVX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
HGHVX - Fund Manager Analysis
Managers
Robert Deresiewicz
Start Date
Tenure
Tenure Rank
May 01, 2000
20.43
20.4%
Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.
Ann Gallo
Start Date
Tenure
Tenure Rank
May 01, 2000
20.43
20.4%
Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.
Jean Hynes
Start Date
Tenure
Tenure Rank
May 01, 2000
20.43
20.4%
Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.
Rebecca Sykes
Start Date
Tenure
Tenure Rank
Sep 01, 2020
0.08
0.1%
Rebecca D. Sykes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, joined Wellington Management in 2007 and has been an investment professional since 2005.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.08 | 23.06 | 7.22 | 20.43 |
